nodes	percent_of_prediction	percent_of_DWPC	metapath
Fluticasone Propionate—PLA2G4A—Epirubicin—bone cancer	0.443	0.98	CbGbCtD
Fluticasone Propionate—CYP3A4—bone cancer	0.429	1	CbGaD
Fluticasone Propionate—CYP3A4—Doxorubicin—bone cancer	0.00924	0.0204	CbGbCtD
Fluticasone Propionate—PLA2G4A—Raltitrexed—Methotrexate—bone cancer	0.00407	1	CbGdCrCtD
Fluticasone Propionate—Fluocinonide—SMO—bone cancer	0.0028	0.484	CrCbGaD
Fluticasone Propionate—NR3C2—Nuclear Receptor transcription pathway—NR1I2—bone cancer	0.00155	0.0446	CbGpPWpGaD
Fluticasone Propionate—NR3C1—Signaling events mediated by HDAC Class II—BCOR—bone cancer	0.00155	0.0445	CbGpPWpGaD
Fluticasone Propionate—CYP3A7—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.00138	0.0396	CbGpPWpGaD
Fluticasone Propionate—PGR—Nuclear Receptors—NR1I2—bone cancer	0.0012	0.0344	CbGpPWpGaD
Fluticasone Propionate—CYP3A5—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.000997	0.0286	CbGpPWpGaD
Fluticasone Propionate—PGR—Nuclear Receptor transcription pathway—NR1I2—bone cancer	0.000947	0.0272	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—ADP signalling through P2Y purinoceptor 1—GNA11—bone cancer	0.000882	0.0253	CbGpPWpGaD
Fluticasone Propionate—NR3C2—Generic Transcription Pathway—ZNF77—bone cancer	0.000793	0.0228	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Signal amplification—GNA11—bone cancer	0.000742	0.0213	CbGpPWpGaD
Fluticasone Propionate—NR3C1—Signaling events mediated by HDAC Class II—TUBB2A—bone cancer	0.000733	0.021	CbGpPWpGaD
Fluticasone Propionate—NR3C1—Serotonin Receptor 4/6/7 and NR3C Signaling—ATF1—bone cancer	0.000722	0.0207	CbGpPWpGaD
Fluticasone Propionate—NR3C1—Nuclear Receptors—NR1I2—bone cancer	0.000692	0.0199	CbGpPWpGaD
Fluticasone Propionate—CYP3A7—Xenobiotics—CYP3A4—bone cancer	0.000666	0.0191	CbGpPWpGaD
Fluticasone Propionate—NR3C1—SIDS Susceptibility Pathways—FEV—bone cancer	0.000661	0.019	CbGpPWpGaD
Fluticasone Propionate—CYP3A5—Irinotecan Pathway—CYP3A4—bone cancer	0.00064	0.0184	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Signaling mediated by p38-alpha and p38-beta—ATF1—bone cancer	0.000626	0.018	CbGpPWpGaD
Fluticasone Propionate—CYP3A7—Metapathway biotransformation—CYP4V2—bone cancer	0.000594	0.017	CbGpPWpGaD
Fluticasone Propionate—Psoriasis—Epirubicin—bone cancer	0.000593	0.0081	CcSEcCtD
Fluticasone Propionate—Oral candidiasis—Epirubicin—bone cancer	0.000587	0.00802	CcSEcCtD
Fluticasone Propionate—Lacrimation—Doxorubicin—bone cancer	0.000587	0.00802	CcSEcCtD
Fluticasone Propionate—Nasal congestion—Cisplatin—bone cancer	0.000579	0.0079	CcSEcCtD
Fluticasone Propionate—Psoriasis—Doxorubicin—bone cancer	0.000549	0.0075	CcSEcCtD
Fluticasone Propionate—Folliculitis—Doxorubicin—bone cancer	0.000549	0.0075	CcSEcCtD
Fluticasone Propionate—NR3C1—Nuclear Receptor transcription pathway—NR1I2—bone cancer	0.000547	0.0157	CbGpPWpGaD
Fluticasone Propionate—Anaphylactoid reaction—Cisplatin—bone cancer	0.000545	0.00744	CcSEcCtD
Fluticasone Propionate—Oral candidiasis—Doxorubicin—bone cancer	0.000543	0.00742	CcSEcCtD
Fluticasone Propionate—Blister—Epirubicin—bone cancer	0.000517	0.00707	CcSEcCtD
Fluticasone Propionate—Face oedema—Cisplatin—bone cancer	0.000509	0.00695	CcSEcCtD
Fluticasone Propionate—Dermatitis atopic—Epirubicin—bone cancer	0.000504	0.00688	CcSEcCtD
Fluticasone Propionate—Irritability—Cisplatin—bone cancer	0.000503	0.00687	CcSEcCtD
Fluticasone Propionate—CYP3A5—Aflatoxin activation and detoxification—CYP3A4—bone cancer	0.000501	0.0144	CbGpPWpGaD
Fluticasone Propionate—PGR—Ovarian Infertility Genes—CDK4—bone cancer	0.000498	0.0143	CbGpPWpGaD
Fluticasone Propionate—Rash erythematous—Epirubicin—bone cancer	0.000487	0.00665	CcSEcCtD
Fluticasone Propionate—PGR—Generic Transcription Pathway—ZNF77—bone cancer	0.000483	0.0139	CbGpPWpGaD
Fluticasone Propionate—CYP3A5—Xenobiotics—CYP3A4—bone cancer	0.000481	0.0138	CbGpPWpGaD
Fluticasone Propionate—Blister—Doxorubicin—bone cancer	0.000479	0.00654	CcSEcCtD
Fluticasone Propionate—Cramp muscle—Cisplatin—bone cancer	0.000475	0.00648	CcSEcCtD
Fluticasone Propionate—Nasopharyngitis—Cisplatin—bone cancer	0.000471	0.00644	CcSEcCtD
Fluticasone Propionate—Dermatitis atopic—Doxorubicin—bone cancer	0.000466	0.00637	CcSEcCtD
Fluticasone Propionate—CYP3A4—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.000464	0.0133	CbGpPWpGaD
Fluticasone Propionate—CYP3A5—Tamoxifen metabolism—CYP3A4—bone cancer	0.000463	0.0133	CbGpPWpGaD
Fluticasone Propionate—Stinging—Epirubicin—bone cancer	0.00046	0.00629	CcSEcCtD
Fluticasone Propionate—Ageusia—Epirubicin—bone cancer	0.00046	0.00629	CcSEcCtD
Fluticasone Propionate—Dysphonia—Epirubicin—bone cancer	0.000453	0.00619	CcSEcCtD
Fluticasone Propionate—Rash erythematous—Doxorubicin—bone cancer	0.00045	0.00615	CcSEcCtD
Fluticasone Propionate—Abdominal discomfort—Cisplatin—bone cancer	0.000437	0.00597	CcSEcCtD
Fluticasone Propionate—CYP3A4—Drug Induction of Bile Acid Pathway—NR1I2—bone cancer	0.000436	0.0125	CbGpPWpGaD
Fluticasone Propionate—Herpes simplex—Methotrexate—bone cancer	0.000432	0.00591	CcSEcCtD
Fluticasone Propionate—CYP3A5—Metapathway biotransformation—CYP4V2—bone cancer	0.000429	0.0123	CbGpPWpGaD
Fluticasone Propionate—Stinging—Doxorubicin—bone cancer	0.000426	0.00582	CcSEcCtD
Fluticasone Propionate—Ageusia—Doxorubicin—bone cancer	0.000426	0.00582	CcSEcCtD
Fluticasone Propionate—PLA2G4A—Endothelins—GNA11—bone cancer	0.000421	0.0121	CbGpPWpGaD
Fluticasone Propionate—Dysphonia—Doxorubicin—bone cancer	0.000419	0.00573	CcSEcCtD
Fluticasone Propionate—Viral infection—Epirubicin—bone cancer	0.000413	0.00564	CcSEcCtD
Fluticasone Propionate—Lacrimation increased—Epirubicin—bone cancer	0.000405	0.00553	CcSEcCtD
Fluticasone Propionate—Herpes simplex—Epirubicin—bone cancer	0.000405	0.00553	CcSEcCtD
Fluticasone Propionate—Conjunctivitis—Cisplatin—bone cancer	0.000395	0.00539	CcSEcCtD
Fluticasone Propionate—NR3C1—Serotonin Receptor 4/6/7 and NR3C Signaling—BRAF—bone cancer	0.000386	0.0111	CbGpPWpGaD
Fluticasone Propionate—Viral infection—Doxorubicin—bone cancer	0.000382	0.00522	CcSEcCtD
Fluticasone Propionate—NR3C2—Gene Expression—ZNF77—bone cancer	0.000382	0.011	CbGpPWpGaD
Fluticasone Propionate—Lacrimation increased—Doxorubicin—bone cancer	0.000374	0.00511	CcSEcCtD
Fluticasone Propionate—Herpes simplex—Doxorubicin—bone cancer	0.000374	0.00511	CcSEcCtD
Fluticasone Propionate—Dermatitis contact—Epirubicin—bone cancer	0.000368	0.00503	CcSEcCtD
Fluticasone Propionate—Influenza like illness—Epirubicin—bone cancer	0.000362	0.00495	CcSEcCtD
Fluticasone Propionate—Fluticasone furoate—CYP3A4—bone cancer	0.000361	0.0625	CrCbGaD
Fluticasone Propionate—Connective tissue disorder—Cisplatin—bone cancer	0.000358	0.0049	CcSEcCtD
Fluticasone Propionate—Candida infection—Epirubicin—bone cancer	0.000356	0.00486	CcSEcCtD
Fluticasone Propionate—Dermatitis contact—Doxorubicin—bone cancer	0.000341	0.00466	CcSEcCtD
Fluticasone Propionate—Eye disorder—Cisplatin—bone cancer	0.000341	0.00466	CcSEcCtD
Fluticasone Propionate—Cardiac disorder—Cisplatin—bone cancer	0.000338	0.00462	CcSEcCtD
Fluticasone Propionate—Influenza like illness—Doxorubicin—bone cancer	0.000335	0.00458	CcSEcCtD
Fluticasone Propionate—Diabetes mellitus—Methotrexate—bone cancer	0.000332	0.00454	CcSEcCtD
Fluticasone Propionate—CYP3A5—Constitutive Androstane Receptor Pathway—CYP3A4—bone cancer	0.00033	0.00948	CbGpPWpGaD
Fluticasone Propionate—Candida infection—Doxorubicin—bone cancer	0.000329	0.0045	CcSEcCtD
Fluticasone Propionate—Immune system disorder—Cisplatin—bone cancer	0.000329	0.0045	CcSEcCtD
Fluticasone Propionate—Mediastinal disorder—Cisplatin—bone cancer	0.000329	0.00449	CcSEcCtD
Fluticasone Propionate—Arrhythmia—Cisplatin—bone cancer	0.000326	0.00445	CcSEcCtD
Fluticasone Propionate—Alclometasone—CYP3A4—bone cancer	0.000318	0.0549	CrCbGaD
Fluticasone Propionate—Malnutrition—Cisplatin—bone cancer	0.000317	0.00434	CcSEcCtD
Fluticasone Propionate—Erythema—Cisplatin—bone cancer	0.000317	0.00434	CcSEcCtD
Fluticasone Propionate—Diabetes mellitus—Epirubicin—bone cancer	0.000311	0.00425	CcSEcCtD
Fluticasone Propionate—Flunisolide—CYP3A4—bone cancer	0.000309	0.0535	CrCbGaD
Fluticasone Propionate—PLA2G4A—Prostaglandin Synthesis and Regulation—PTGS2—bone cancer	0.000306	0.00878	CbGpPWpGaD
Fluticasone Propionate—Paramethasone—CYP3A4—bone cancer	0.000305	0.0528	CrCbGaD
Fluticasone Propionate—Muscle spasms—Cisplatin—bone cancer	0.000305	0.00417	CcSEcCtD
Fluticasone Propionate—Eczema—Epirubicin—bone cancer	0.000301	0.00411	CcSEcCtD
Fluticasone Propionate—Vision blurred—Cisplatin—bone cancer	0.000299	0.00409	CcSEcCtD
Fluticasone Propionate—Anaphylactoid reaction—Methotrexate—bone cancer	0.000299	0.00408	CcSEcCtD
Fluticasone Propionate—Fluorometholone—CYP3A4—bone cancer	0.000298	0.0515	CrCbGaD
Fluticasone Propionate—Tremor—Cisplatin—bone cancer	0.000297	0.00406	CcSEcCtD
Fluticasone Propionate—Ill-defined disorder—Cisplatin—bone cancer	0.000294	0.00402	CcSEcCtD
Fluticasone Propionate—Methylprednisolone—CYP3A4—bone cancer	0.000288	0.0498	CrCbGaD
Fluticasone Propionate—Diabetes mellitus—Doxorubicin—bone cancer	0.000288	0.00393	CcSEcCtD
Fluticasone Propionate—Malaise—Cisplatin—bone cancer	0.000286	0.00391	CcSEcCtD
Fluticasone Propionate—Dermatitis bullous—Epirubicin—bone cancer	0.000283	0.00387	CcSEcCtD
Fluticasone Propionate—Anaphylactoid reaction—Epirubicin—bone cancer	0.00028	0.00382	CcSEcCtD
Fluticasone Propionate—NR3C1—Generic Transcription Pathway—ZNF77—bone cancer	0.000279	0.00801	CbGpPWpGaD
Fluticasone Propionate—NR3C1—Endoderm Differentiation—EZH2—bone cancer	0.000279	0.008	CbGpPWpGaD
Fluticasone Propionate—Eczema—Doxorubicin—bone cancer	0.000279	0.00381	CcSEcCtD
Fluticasone Propionate—CYP3A7—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.000276	0.00793	CbGpPWpGaD
Fluticasone Propionate—Irritability—Methotrexate—bone cancer	0.000276	0.00377	CcSEcCtD
Fluticasone Propionate—CYP3A7—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.000273	0.00783	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Signaling mediated by p38-alpha and p38-beta—PTGS2—bone cancer	0.000271	0.00776	CbGpPWpGaD
Fluticasone Propionate—Anxiety—Cisplatin—bone cancer	0.000269	0.00368	CcSEcCtD
Fluticasone Propionate—NR3C2—Generic Transcription Pathway—NR1I2—bone cancer	0.000269	0.0077	CbGpPWpGaD
Fluticasone Propionate—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—bone cancer	0.000268	0.00367	CcSEcCtD
Fluticasone Propionate—Discomfort—Cisplatin—bone cancer	0.000267	0.00365	CcSEcCtD
Fluticasone Propionate—Dermatitis bullous—Doxorubicin—bone cancer	0.000262	0.00358	CcSEcCtD
Fluticasone Propionate—Face oedema—Epirubicin—bone cancer	0.000261	0.00357	CcSEcCtD
Fluticasone Propionate—Oedema—Cisplatin—bone cancer	0.000259	0.00354	CcSEcCtD
Fluticasone Propionate—Anaphylactic shock—Cisplatin—bone cancer	0.000259	0.00354	CcSEcCtD
Fluticasone Propionate—Anaphylactoid reaction—Doxorubicin—bone cancer	0.000259	0.00354	CcSEcCtD
Fluticasone Propionate—Infection—Cisplatin—bone cancer	0.000257	0.00352	CcSEcCtD
Fluticasone Propionate—Nervous system disorder—Cisplatin—bone cancer	0.000254	0.00347	CcSEcCtD
Fluticasone Propionate—Tachycardia—Cisplatin—bone cancer	0.000253	0.00345	CcSEcCtD
Fluticasone Propionate—Skin disorder—Cisplatin—bone cancer	0.000252	0.00344	CcSEcCtD
Fluticasone Propionate—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I2—bone cancer	0.000251	0.00719	CbGpPWpGaD
Fluticasone Propionate—Asthma—Methotrexate—bone cancer	0.00025	0.00342	CcSEcCtD
Fluticasone Propionate—PLA2G4A—Signaling mediated by p38-alpha and p38-beta—JUN—bone cancer	0.000244	0.007	CbGpPWpGaD
Fluticasone Propionate—Triamcinolone—CYP3A4—bone cancer	0.000243	0.042	CrCbGaD
Fluticasone Propionate—Nasopharyngitis—Epirubicin—bone cancer	0.000242	0.00331	CcSEcCtD
Fluticasone Propionate—Face oedema—Doxorubicin—bone cancer	0.000242	0.0033	CcSEcCtD
Fluticasone Propionate—Abdominal discomfort—Methotrexate—bone cancer	0.00024	0.00327	CcSEcCtD
Fluticasone Propionate—Triamcinolone—PTGS2—bone cancer	0.000238	0.0411	CrCbGaD
Fluticasone Propionate—Musculoskeletal discomfort—Cisplatin—bone cancer	0.000236	0.00322	CcSEcCtD
Fluticasone Propionate—Abdominal distension—Epirubicin—bone cancer	0.000235	0.00322	CcSEcCtD
Fluticasone Propionate—Asthma—Epirubicin—bone cancer	0.000234	0.0032	CcSEcCtD
Fluticasone Propionate—PGR—Gene Expression—ZNF77—bone cancer	0.000233	0.00667	CbGpPWpGaD
Fluticasone Propionate—Upper respiratory tract infection—Methotrexate—bone cancer	0.000232	0.00317	CcSEcCtD
Fluticasone Propionate—Dyspnoea—Cisplatin—bone cancer	0.000231	0.00316	CcSEcCtD
Fluticasone Propionate—Bronchitis—Epirubicin—bone cancer	0.000225	0.00307	CcSEcCtD
Fluticasone Propionate—Pneumonia—Methotrexate—bone cancer	0.000224	0.00306	CcSEcCtD
Fluticasone Propionate—CYP3A7—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.000224	0.00643	CbGpPWpGaD
Fluticasone Propionate—Nasopharyngitis—Doxorubicin—bone cancer	0.000224	0.00306	CcSEcCtD
Fluticasone Propionate—PLA2G4A—PDGF Pathway—JUN—bone cancer	0.000224	0.00642	CbGpPWpGaD
Fluticasone Propionate—Infestation NOS—Methotrexate—bone cancer	0.000223	0.00304	CcSEcCtD
Fluticasone Propionate—Infestation—Methotrexate—bone cancer	0.000223	0.00304	CcSEcCtD
Fluticasone Propionate—PLA2G4A—Integrated Pancreatic Cancer Pathway—WT1—bone cancer	0.000223	0.00639	CbGpPWpGaD
Fluticasone Propionate—Pain—Cisplatin—bone cancer	0.000222	0.00303	CcSEcCtD
Fluticasone Propionate—Abdominal distension—Doxorubicin—bone cancer	0.000218	0.00298	CcSEcCtD
Fluticasone Propionate—Upper respiratory tract infection—Epirubicin—bone cancer	0.000217	0.00297	CcSEcCtD
Fluticasone Propionate—Conjunctivitis—Methotrexate—bone cancer	0.000217	0.00296	CcSEcCtD
Fluticasone Propionate—Asthma—Doxorubicin—bone cancer	0.000216	0.00296	CcSEcCtD
Fluticasone Propionate—Feeling abnormal—Cisplatin—bone cancer	0.000213	0.00292	CcSEcCtD
Fluticasone Propionate—Hyperglycaemia—Epirubicin—bone cancer	0.000211	0.00288	CcSEcCtD
Fluticasone Propionate—Epistaxis—Methotrexate—bone cancer	0.00021	0.00287	CcSEcCtD
Fluticasone Propionate—Pneumonia—Epirubicin—bone cancer	0.00021	0.00287	CcSEcCtD
Fluticasone Propionate—Infestation NOS—Epirubicin—bone cancer	0.000209	0.00285	CcSEcCtD
Fluticasone Propionate—Infestation—Epirubicin—bone cancer	0.000209	0.00285	CcSEcCtD
Fluticasone Propionate—Bronchitis—Doxorubicin—bone cancer	0.000208	0.00284	CcSEcCtD
Fluticasone Propionate—Body temperature increased—Cisplatin—bone cancer	0.000205	0.0028	CcSEcCtD
Fluticasone Propionate—PLA2G4A—Arachidonic acid metabolism—PTGS2—bone cancer	0.000203	0.00584	CbGpPWpGaD
Fluticasone Propionate—Conjunctivitis—Epirubicin—bone cancer	0.000203	0.00277	CcSEcCtD
Fluticasone Propionate—Upper respiratory tract infection—Doxorubicin—bone cancer	0.000201	0.00275	CcSEcCtD
Fluticasone Propionate—CYP3A5—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.0002	0.00573	CbGpPWpGaD
Fluticasone Propionate—CYP3A4—Metapathway biotransformation—CYP4V2—bone cancer	0.0002	0.00573	CbGpPWpGaD
Fluticasone Propionate—Betamethasone—CYP3A4—bone cancer	0.000199	0.0344	CrCbGaD
Fluticasone Propionate—Pharyngitis—Methotrexate—bone cancer	0.000199	0.00271	CcSEcCtD
Fluticasone Propionate—CYP3A5—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.000197	0.00566	CbGpPWpGaD
Fluticasone Propionate—Epistaxis—Epirubicin—bone cancer	0.000197	0.00269	CcSEcCtD
Fluticasone Propionate—Sinusitis—Epirubicin—bone cancer	0.000196	0.00267	CcSEcCtD
Fluticasone Propionate—Hyperglycaemia—Doxorubicin—bone cancer	0.000195	0.00267	CcSEcCtD
Fluticasone Propionate—Betamethasone—PTGS2—bone cancer	0.000195	0.0337	CrCbGaD
Fluticasone Propionate—Pneumonia—Doxorubicin—bone cancer	0.000194	0.00265	CcSEcCtD
Fluticasone Propionate—Infestation—Doxorubicin—bone cancer	0.000193	0.00264	CcSEcCtD
Fluticasone Propionate—Infestation NOS—Doxorubicin—bone cancer	0.000193	0.00264	CcSEcCtD
Fluticasone Propionate—Hypersensitivity—Cisplatin—bone cancer	0.000191	0.00261	CcSEcCtD
Fluticasone Propionate—PLA2G4A—AGE/RAGE pathway—MMP2—bone cancer	0.00019	0.00545	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Integrated Pancreatic Cancer Pathway—SMO—bone cancer	0.000189	0.00544	CbGpPWpGaD
Fluticasone Propionate—Conjunctivitis—Doxorubicin—bone cancer	0.000188	0.00256	CcSEcCtD
Fluticasone Propionate—Eye disorder—Methotrexate—bone cancer	0.000187	0.00255	CcSEcCtD
Fluticasone Propionate—NR3C2—Gene Expression—FUS—bone cancer	0.000187	0.00535	CbGpPWpGaD
Fluticasone Propionate—Hypoaesthesia—Epirubicin—bone cancer	0.000186	0.00255	CcSEcCtD
Fluticasone Propionate—Pharyngitis—Epirubicin—bone cancer	0.000186	0.00254	CcSEcCtD
Fluticasone Propionate—Cardiac disorder—Methotrexate—bone cancer	0.000186	0.00254	CcSEcCtD
Fluticasone Propionate—PGR—Validated nuclear estrogen receptor alpha network—JUN—bone cancer	0.000184	0.00529	CbGpPWpGaD
Fluticasone Propionate—Connective tissue disorder—Epirubicin—bone cancer	0.000184	0.00251	CcSEcCtD
Fluticasone Propionate—Epistaxis—Doxorubicin—bone cancer	0.000182	0.00249	CcSEcCtD
Fluticasone Propionate—Sinusitis—Doxorubicin—bone cancer	0.000181	0.00247	CcSEcCtD
Fluticasone Propionate—Immune system disorder—Methotrexate—bone cancer	0.000181	0.00247	CcSEcCtD
Fluticasone Propionate—Mediastinal disorder—Methotrexate—bone cancer	0.00018	0.00246	CcSEcCtD
Fluticasone Propionate—Diarrhoea—Cisplatin—bone cancer	0.000177	0.00242	CcSEcCtD
Fluticasone Propionate—Mental disorder—Methotrexate—bone cancer	0.000175	0.00239	CcSEcCtD
Fluticasone Propionate—Eye disorder—Epirubicin—bone cancer	0.000175	0.00239	CcSEcCtD
Fluticasone Propionate—Malnutrition—Methotrexate—bone cancer	0.000174	0.00238	CcSEcCtD
Fluticasone Propionate—Erythema—Methotrexate—bone cancer	0.000174	0.00238	CcSEcCtD
Fluticasone Propionate—Cardiac disorder—Epirubicin—bone cancer	0.000174	0.00237	CcSEcCtD
Fluticasone Propionate—PLA2G4A—Integrated Pancreatic Cancer Pathway—EZH2—bone cancer	0.000173	0.00495	CbGpPWpGaD
Fluticasone Propionate—Hypoaesthesia—Doxorubicin—bone cancer	0.000172	0.00236	CcSEcCtD
Fluticasone Propionate—Pharyngitis—Doxorubicin—bone cancer	0.000172	0.00235	CcSEcCtD
Fluticasone Propionate—Connective tissue disorder—Doxorubicin—bone cancer	0.00017	0.00233	CcSEcCtD
Fluticasone Propionate—Immune system disorder—Epirubicin—bone cancer	0.000169	0.00231	CcSEcCtD
Fluticasone Propionate—Mediastinal disorder—Epirubicin—bone cancer	0.000169	0.00231	CcSEcCtD
Fluticasone Propionate—PLA2G4A—Platelet activation, signaling and aggregation—SPARC—bone cancer	0.000169	0.00484	CbGpPWpGaD
Fluticasone Propionate—Arrhythmia—Epirubicin—bone cancer	0.000167	0.00229	CcSEcCtD
Fluticasone Propionate—Vomiting—Cisplatin—bone cancer	0.000165	0.00225	CcSEcCtD
Fluticasone Propionate—Vision blurred—Methotrexate—bone cancer	0.000164	0.00224	CcSEcCtD
Fluticasone Propionate—Mental disorder—Epirubicin—bone cancer	0.000164	0.00224	CcSEcCtD
Fluticasone Propionate—PGR—Generic Transcription Pathway—NR1I2—bone cancer	0.000164	0.00469	CbGpPWpGaD
Fluticasone Propionate—Rash—Cisplatin—bone cancer	0.000163	0.00223	CcSEcCtD
Fluticasone Propionate—Dermatitis—Cisplatin—bone cancer	0.000163	0.00223	CcSEcCtD
Fluticasone Propionate—Erythema—Epirubicin—bone cancer	0.000163	0.00223	CcSEcCtD
Fluticasone Propionate—Malnutrition—Epirubicin—bone cancer	0.000163	0.00223	CcSEcCtD
Fluticasone Propionate—NR3C1—AP-1 transcription factor network—PLAU—bone cancer	0.000163	0.00467	CbGpPWpGaD
Fluticasone Propionate—CYP3A5—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.000162	0.00465	CbGpPWpGaD
Fluticasone Propionate—Eye disorder—Doxorubicin—bone cancer	0.000162	0.00221	CcSEcCtD
Fluticasone Propionate—Ill-defined disorder—Methotrexate—bone cancer	0.000162	0.00221	CcSEcCtD
Fluticasone Propionate—PLA2G4A—Signaling mediated by p38-alpha and p38-beta—TP53—bone cancer	0.000161	0.00462	CbGpPWpGaD
Fluticasone Propionate—Cardiac disorder—Doxorubicin—bone cancer	0.000161	0.0022	CcSEcCtD
Fluticasone Propionate—PLA2G4A—Integrated Pancreatic Cancer Pathway—IL3—bone cancer	0.000157	0.00451	CbGpPWpGaD
Fluticasone Propionate—Malaise—Methotrexate—bone cancer	0.000157	0.00215	CcSEcCtD
Fluticasone Propionate—Muscle spasms—Epirubicin—bone cancer	0.000157	0.00214	CcSEcCtD
Fluticasone Propionate—Immune system disorder—Doxorubicin—bone cancer	0.000156	0.00214	CcSEcCtD
Fluticasone Propionate—PLA2G4A—Fc-epsilon receptor I signaling in mast cells—JUN—bone cancer	0.000156	0.00449	CbGpPWpGaD
Fluticasone Propionate—Mediastinal disorder—Doxorubicin—bone cancer	0.000156	0.00213	CcSEcCtD
Fluticasone Propionate—PLA2G4A—Integrated Pancreatic Cancer Pathway—CHEK2—bone cancer	0.000155	0.00445	CbGpPWpGaD
Fluticasone Propionate—Arrhythmia—Doxorubicin—bone cancer	0.000155	0.00211	CcSEcCtD
Fluticasone Propionate—PLA2G4A—Platelet activation, signaling and aggregation—GNA11—bone cancer	0.000154	0.00442	CbGpPWpGaD
Fluticasone Propionate—Nausea—Cisplatin—bone cancer	0.000154	0.0021	CcSEcCtD
Fluticasone Propionate—Vision blurred—Epirubicin—bone cancer	0.000154	0.0021	CcSEcCtD
Fluticasone Propionate—PLA2G4A—Endothelins—JUN—bone cancer	0.000152	0.00437	CbGpPWpGaD
Fluticasone Propionate—Cough—Methotrexate—bone cancer	0.000152	0.00208	CcSEcCtD
Fluticasone Propionate—Mental disorder—Doxorubicin—bone cancer	0.000152	0.00207	CcSEcCtD
Fluticasone Propionate—Ill-defined disorder—Epirubicin—bone cancer	0.000151	0.00207	CcSEcCtD
Fluticasone Propionate—Erythema—Doxorubicin—bone cancer	0.000151	0.00206	CcSEcCtD
Fluticasone Propionate—Malnutrition—Doxorubicin—bone cancer	0.000151	0.00206	CcSEcCtD
Fluticasone Propionate—Agitation—Epirubicin—bone cancer	0.00015	0.00205	CcSEcCtD
Fluticasone Propionate—Arthralgia—Methotrexate—bone cancer	0.000148	0.00203	CcSEcCtD
Fluticasone Propionate—Chest pain—Methotrexate—bone cancer	0.000148	0.00203	CcSEcCtD
Fluticasone Propionate—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—bone cancer	0.000147	0.00201	CcSEcCtD
Fluticasone Propionate—Malaise—Epirubicin—bone cancer	0.000147	0.00201	CcSEcCtD
Fluticasone Propionate—PLA2G4A—AGE/RAGE pathway—JUN—bone cancer	0.000147	0.00421	CbGpPWpGaD
Fluticasone Propionate—Discomfort—Methotrexate—bone cancer	0.000146	0.002	CcSEcCtD
Fluticasone Propionate—Muscle spasms—Doxorubicin—bone cancer	0.000145	0.00198	CcSEcCtD
Fluticasone Propionate—Palpitations—Epirubicin—bone cancer	0.000144	0.00197	CcSEcCtD
Fluticasone Propionate—PLA2G4A—AGE/RAGE pathway—MMP9—bone cancer	0.000143	0.0041	CbGpPWpGaD
Fluticasone Propionate—NR3C1—Regulation of Androgen receptor activity—MDM2—bone cancer	0.000142	0.00409	CbGpPWpGaD
Fluticasone Propionate—Cough—Epirubicin—bone cancer	0.000142	0.00194	CcSEcCtD
Fluticasone Propionate—Anaphylactic shock—Methotrexate—bone cancer	0.000142	0.00194	CcSEcCtD
Fluticasone Propionate—Vision blurred—Doxorubicin—bone cancer	0.000142	0.00194	CcSEcCtD
Fluticasone Propionate—Infection—Methotrexate—bone cancer	0.000141	0.00193	CcSEcCtD
Fluticasone Propionate—Hypertension—Epirubicin—bone cancer	0.000141	0.00192	CcSEcCtD
Fluticasone Propionate—Ill-defined disorder—Doxorubicin—bone cancer	0.00014	0.00191	CcSEcCtD
Fluticasone Propionate—PLA2G4A—Platelet activation, signaling and aggregation—IL3—bone cancer	0.00014	0.00401	CbGpPWpGaD
Fluticasone Propionate—Nervous system disorder—Methotrexate—bone cancer	0.000139	0.0019	CcSEcCtD
Fluticasone Propionate—Chest pain—Epirubicin—bone cancer	0.000139	0.0019	CcSEcCtD
Fluticasone Propionate—Arthralgia—Epirubicin—bone cancer	0.000139	0.0019	CcSEcCtD
Fluticasone Propionate—Agitation—Doxorubicin—bone cancer	0.000139	0.00189	CcSEcCtD
Fluticasone Propionate—Anxiety—Epirubicin—bone cancer	0.000138	0.00189	CcSEcCtD
Fluticasone Propionate—Skin disorder—Methotrexate—bone cancer	0.000138	0.00189	CcSEcCtD
Fluticasone Propionate—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—bone cancer	0.000138	0.00188	CcSEcCtD
Fluticasone Propionate—Discomfort—Epirubicin—bone cancer	0.000137	0.00187	CcSEcCtD
Fluticasone Propionate—NR3C1—Regulation of nuclear SMAD2/3 signaling—CDK4—bone cancer	0.000137	0.00393	CbGpPWpGaD
Fluticasone Propionate—Malaise—Doxorubicin—bone cancer	0.000136	0.00186	CcSEcCtD
Fluticasone Propionate—Dry mouth—Epirubicin—bone cancer	0.000136	0.00185	CcSEcCtD
Fluticasone Propionate—PGR—Signaling by ERBB4—KIT—bone cancer	0.000135	0.00387	CbGpPWpGaD
Fluticasone Propionate—NR3C1—Gene Expression—ZNF77—bone cancer	0.000134	0.00386	CbGpPWpGaD
Fluticasone Propionate—Palpitations—Doxorubicin—bone cancer	0.000133	0.00182	CcSEcCtD
Fluticasone Propionate—Anaphylactic shock—Epirubicin—bone cancer	0.000133	0.00182	CcSEcCtD
Fluticasone Propionate—Oedema—Epirubicin—bone cancer	0.000133	0.00182	CcSEcCtD
Fluticasone Propionate—Infection—Epirubicin—bone cancer	0.000132	0.00181	CcSEcCtD
Fluticasone Propionate—Cough—Doxorubicin—bone cancer	0.000132	0.0018	CcSEcCtD
Fluticasone Propionate—PLA2G4A—Integrated Pancreatic Cancer Pathway—BRCA2—bone cancer	0.000131	0.00377	CbGpPWpGaD
Fluticasone Propionate—Nervous system disorder—Epirubicin—bone cancer	0.00013	0.00178	CcSEcCtD
Fluticasone Propionate—Hypertension—Doxorubicin—bone cancer	0.00013	0.00178	CcSEcCtD
Fluticasone Propionate—Tachycardia—Epirubicin—bone cancer	0.00013	0.00177	CcSEcCtD
Fluticasone Propionate—Musculoskeletal discomfort—Methotrexate—bone cancer	0.00013	0.00177	CcSEcCtD
Fluticasone Propionate—NR3C2—Gene Expression—NR1I2—bone cancer	0.000129	0.00371	CbGpPWpGaD
Fluticasone Propionate—Skin disorder—Epirubicin—bone cancer	0.000129	0.00177	CcSEcCtD
Fluticasone Propionate—Arthralgia—Doxorubicin—bone cancer	0.000128	0.00175	CcSEcCtD
Fluticasone Propionate—Chest pain—Doxorubicin—bone cancer	0.000128	0.00175	CcSEcCtD
Fluticasone Propionate—Anxiety—Doxorubicin—bone cancer	0.000128	0.00175	CcSEcCtD
Fluticasone Propionate—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—bone cancer	0.000128	0.00174	CcSEcCtD
Fluticasone Propionate—Discomfort—Doxorubicin—bone cancer	0.000127	0.00173	CcSEcCtD
Fluticasone Propionate—Dyspnoea—Methotrexate—bone cancer	0.000127	0.00173	CcSEcCtD
Fluticasone Propionate—Dry mouth—Doxorubicin—bone cancer	0.000126	0.00172	CcSEcCtD
Fluticasone Propionate—NR3C1—Regulation of Androgen receptor activity—JUN—bone cancer	0.000124	0.00355	CbGpPWpGaD
Fluticasone Propionate—Anaphylactic shock—Doxorubicin—bone cancer	0.000123	0.00168	CcSEcCtD
Fluticasone Propionate—Oedema—Doxorubicin—bone cancer	0.000123	0.00168	CcSEcCtD
Fluticasone Propionate—Infection—Doxorubicin—bone cancer	0.000122	0.00167	CcSEcCtD
Fluticasone Propionate—Pain—Methotrexate—bone cancer	0.000122	0.00166	CcSEcCtD
Fluticasone Propionate—Musculoskeletal discomfort—Epirubicin—bone cancer	0.000121	0.00166	CcSEcCtD
Fluticasone Propionate—PLA2G4A—PDGFR-beta signaling pathway—BRAF—bone cancer	0.000121	0.00347	CbGpPWpGaD
Fluticasone Propionate—Nervous system disorder—Doxorubicin—bone cancer	0.000121	0.00165	CcSEcCtD
Fluticasone Propionate—Tachycardia—Doxorubicin—bone cancer	0.00012	0.00164	CcSEcCtD
Fluticasone Propionate—Skin disorder—Doxorubicin—bone cancer	0.00012	0.00163	CcSEcCtD
Fluticasone Propionate—CYP3A7—Biological oxidations—CYP3A4—bone cancer	0.000119	0.00342	CbGpPWpGaD
Fluticasone Propionate—Dyspnoea—Epirubicin—bone cancer	0.000119	0.00162	CcSEcCtD
Fluticasone Propionate—CYP3A7—Metapathway biotransformation—CYP3A4—bone cancer	0.000117	0.00337	CbGpPWpGaD
Fluticasone Propionate—Feeling abnormal—Methotrexate—bone cancer	0.000117	0.0016	CcSEcCtD
Fluticasone Propionate—Gastrointestinal pain—Methotrexate—bone cancer	0.000116	0.00159	CcSEcCtD
Fluticasone Propionate—Dexamethasone—CYP3A4—bone cancer	0.000116	0.02	CrCbGaD
Fluticasone Propionate—PLA2G4A—AGE/RAGE pathway—EGFR—bone cancer	0.000115	0.00331	CbGpPWpGaD
Fluticasone Propionate—Pain—Epirubicin—bone cancer	0.000114	0.00155	CcSEcCtD
Fluticasone Propionate—PGR—Gene Expression—FUS—bone cancer	0.000114	0.00326	CbGpPWpGaD
Fluticasone Propionate—Dexamethasone—PTGS2—bone cancer	0.000113	0.0196	CrCbGaD
Fluticasone Propionate—Urticaria—Methotrexate—bone cancer	0.000113	0.00154	CcSEcCtD
Fluticasone Propionate—Abdominal pain—Methotrexate—bone cancer	0.000112	0.00154	CcSEcCtD
Fluticasone Propionate—Body temperature increased—Methotrexate—bone cancer	0.000112	0.00154	CcSEcCtD
Fluticasone Propionate—Musculoskeletal discomfort—Doxorubicin—bone cancer	0.000112	0.00153	CcSEcCtD
Fluticasone Propionate—Dyspnoea—Doxorubicin—bone cancer	0.00011	0.0015	CcSEcCtD
Fluticasone Propionate—Feeling abnormal—Epirubicin—bone cancer	0.00011	0.0015	CcSEcCtD
Fluticasone Propionate—Gastrointestinal pain—Epirubicin—bone cancer	0.000109	0.00149	CcSEcCtD
Fluticasone Propionate—PGR—Signaling by ERBB4—MDM2—bone cancer	0.000106	0.00304	CbGpPWpGaD
Fluticasone Propionate—Urticaria—Epirubicin—bone cancer	0.000106	0.00144	CcSEcCtD
Fluticasone Propionate—Pain—Doxorubicin—bone cancer	0.000105	0.00144	CcSEcCtD
Fluticasone Propionate—Abdominal pain—Epirubicin—bone cancer	0.000105	0.00144	CcSEcCtD
Fluticasone Propionate—Body temperature increased—Epirubicin—bone cancer	0.000105	0.00144	CcSEcCtD
Fluticasone Propionate—Hypersensitivity—Methotrexate—bone cancer	0.000105	0.00143	CcSEcCtD
Fluticasone Propionate—PLA2G4A—Metabolism—NDUFA12—bone cancer	0.000102	0.00294	CbGpPWpGaD
Fluticasone Propionate—CYP3A7—Biological oxidations—GSTP1—bone cancer	0.000102	0.00292	CbGpPWpGaD
Fluticasone Propionate—Feeling abnormal—Doxorubicin—bone cancer	0.000101	0.00139	CcSEcCtD
Fluticasone Propionate—Gastrointestinal pain—Doxorubicin—bone cancer	0.000101	0.00138	CcSEcCtD
Fluticasone Propionate—Pruritus—Methotrexate—bone cancer	0.000101	0.00137	CcSEcCtD
Fluticasone Propionate—NR3C1—Glucocorticoid receptor regulatory network—MDM2—bone cancer	0.0001	0.00288	CbGpPWpGaD
Fluticasone Propionate—CYP3A7—Metapathway biotransformation—GSTP1—bone cancer	0.0001	0.00288	CbGpPWpGaD
Fluticasone Propionate—NR3C1—AP-1 transcription factor network—JUN—bone cancer	9.91e-05	0.00284	CbGpPWpGaD
Fluticasone Propionate—Hypersensitivity—Epirubicin—bone cancer	9.8e-05	0.00134	CcSEcCtD
Fluticasone Propionate—Urticaria—Doxorubicin—bone cancer	9.78e-05	0.00134	CcSEcCtD
Fluticasone Propionate—PLA2G4A—Integrated Pancreatic Cancer Pathway—CDK4—bone cancer	9.74e-05	0.00279	CbGpPWpGaD
Fluticasone Propionate—Abdominal pain—Doxorubicin—bone cancer	9.73e-05	0.00133	CcSEcCtD
Fluticasone Propionate—Body temperature increased—Doxorubicin—bone cancer	9.73e-05	0.00133	CcSEcCtD
Fluticasone Propionate—Diarrhoea—Methotrexate—bone cancer	9.73e-05	0.00133	CcSEcCtD
Fluticasone Propionate—NR3C1—AP-1 transcription factor network—MMP9—bone cancer	9.65e-05	0.00277	CbGpPWpGaD
Fluticasone Propionate—NR3C2—Gene Expression—EIF2S1—bone cancer	9.55e-05	0.00274	CbGpPWpGaD
Fluticasone Propionate—NR3C1—Generic Transcription Pathway—NR1I2—bone cancer	9.45e-05	0.00271	CbGpPWpGaD
Fluticasone Propionate—Pruritus—Epirubicin—bone cancer	9.41e-05	0.00129	CcSEcCtD
Fluticasone Propionate—Dizziness—Methotrexate—bone cancer	9.4e-05	0.00128	CcSEcCtD
Fluticasone Propionate—Diarrhoea—Epirubicin—bone cancer	9.1e-05	0.00124	CcSEcCtD
Fluticasone Propionate—Hypersensitivity—Doxorubicin—bone cancer	9.07e-05	0.00124	CcSEcCtD
Fluticasone Propionate—Vomiting—Methotrexate—bone cancer	9.04e-05	0.00123	CcSEcCtD
Fluticasone Propionate—Rash—Methotrexate—bone cancer	8.96e-05	0.00122	CcSEcCtD
Fluticasone Propionate—Dermatitis—Methotrexate—bone cancer	8.95e-05	0.00122	CcSEcCtD
Fluticasone Propionate—Headache—Methotrexate—bone cancer	8.9e-05	0.00122	CcSEcCtD
Fluticasone Propionate—NR3C1—Regulation of nuclear SMAD2/3 signaling—JUN—bone cancer	8.82e-05	0.00253	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—PDGFR-beta signaling pathway—JUN—bone cancer	8.81e-05	0.00253	CbGpPWpGaD
Fluticasone Propionate—Dizziness—Epirubicin—bone cancer	8.8e-05	0.0012	CcSEcCtD
Fluticasone Propionate—NR3C1—Glucocorticoid receptor regulatory network—JUN—bone cancer	8.74e-05	0.00251	CbGpPWpGaD
Fluticasone Propionate—Pruritus—Doxorubicin—bone cancer	8.71e-05	0.00119	CcSEcCtD
Fluticasone Propionate—PLA2G4A—Hemostasis—SPARC—bone cancer	8.69e-05	0.00249	CbGpPWpGaD
Fluticasone Propionate—CYP3A5—Biological oxidations—CYP3A4—bone cancer	8.61e-05	0.00247	CbGpPWpGaD
Fluticasone Propionate—CYP3A5—Metapathway biotransformation—CYP3A4—bone cancer	8.49e-05	0.00244	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Metabolism—NT5C3A—bone cancer	8.49e-05	0.00243	CbGpPWpGaD
Fluticasone Propionate—Vomiting—Epirubicin—bone cancer	8.46e-05	0.00116	CcSEcCtD
Fluticasone Propionate—Nausea—Methotrexate—bone cancer	8.44e-05	0.00115	CcSEcCtD
Fluticasone Propionate—Diarrhoea—Doxorubicin—bone cancer	8.42e-05	0.00115	CcSEcCtD
Fluticasone Propionate—Rash—Epirubicin—bone cancer	8.39e-05	0.00115	CcSEcCtD
Fluticasone Propionate—Dermatitis—Epirubicin—bone cancer	8.38e-05	0.00114	CcSEcCtD
Fluticasone Propionate—Headache—Epirubicin—bone cancer	8.33e-05	0.00114	CcSEcCtD
Fluticasone Propionate—NR3C2—Gene Expression—EZH2—bone cancer	8.29e-05	0.00238	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Signaling by GPCR—GRM4—bone cancer	8.16e-05	0.00234	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Signaling by GPCR—RGS1—bone cancer	8.16e-05	0.00234	CbGpPWpGaD
Fluticasone Propionate—NR3C1—Adipogenesis—RB1—bone cancer	8.15e-05	0.00234	CbGpPWpGaD
Fluticasone Propionate—Dizziness—Doxorubicin—bone cancer	8.14e-05	0.00111	CcSEcCtD
Fluticasone Propionate—PLA2G4A—Hemostasis—GNA11—bone cancer	7.95e-05	0.00228	CbGpPWpGaD
Fluticasone Propionate—Nausea—Epirubicin—bone cancer	7.9e-05	0.00108	CcSEcCtD
Fluticasone Propionate—PGR—Gene Expression—NR1I2—bone cancer	7.87e-05	0.00226	CbGpPWpGaD
Fluticasone Propionate—Vomiting—Doxorubicin—bone cancer	7.83e-05	0.00107	CcSEcCtD
Fluticasone Propionate—Rash—Doxorubicin—bone cancer	7.76e-05	0.00106	CcSEcCtD
Fluticasone Propionate—Dermatitis—Doxorubicin—bone cancer	7.75e-05	0.00106	CcSEcCtD
Fluticasone Propionate—Headache—Doxorubicin—bone cancer	7.71e-05	0.00105	CcSEcCtD
Fluticasone Propionate—CYP3A5—Biological oxidations—GSTP1—bone cancer	7.36e-05	0.00211	CbGpPWpGaD
Fluticasone Propionate—Nausea—Doxorubicin—bone cancer	7.31e-05	0.000999	CcSEcCtD
Fluticasone Propionate—CYP3A5—Metapathway biotransformation—GSTP1—bone cancer	7.26e-05	0.00208	CbGpPWpGaD
Fluticasone Propionate—PGR—Signaling by ERBB4—EGFR—bone cancer	7.25e-05	0.00208	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Integrated Pancreatic Cancer Pathway—MDM2—bone cancer	7.22e-05	0.00207	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Hemostasis—IL3—bone cancer	7.21e-05	0.00207	CbGpPWpGaD
Fluticasone Propionate—CYP3A7—Metabolism—NDUFA12—bone cancer	7.14e-05	0.00205	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Signaling by GPCR—GRM1—bone cancer	7.08e-05	0.00203	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Integrated Pancreatic Cancer Pathway—PTGS2—bone cancer	6.96e-05	0.002	CbGpPWpGaD
Fluticasone Propionate—NR3C1—Gene Expression—FUS—bone cancer	6.57e-05	0.00188	CbGpPWpGaD
Fluticasone Propionate—NR3C1—AP-1 transcription factor network—TP53—bone cancer	6.54e-05	0.00188	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Integrated Pancreatic Cancer Pathway—JUN—bone cancer	6.28e-05	0.0018	CbGpPWpGaD
Fluticasone Propionate—CYP3A7—Metabolism—NT5C3A—bone cancer	5.91e-05	0.0017	CbGpPWpGaD
Fluticasone Propionate—PGR—Signaling Pathways—GRM4—bone cancer	5.9e-05	0.00169	CbGpPWpGaD
Fluticasone Propionate—PGR—Signaling Pathways—RGS1—bone cancer	5.9e-05	0.00169	CbGpPWpGaD
Fluticasone Propionate—PGR—Gene Expression—EIF2S1—bone cancer	5.81e-05	0.00167	CbGpPWpGaD
Fluticasone Propionate—NR3C1—Glucocorticoid receptor regulatory network—TP53—bone cancer	5.77e-05	0.00165	CbGpPWpGaD
Fluticasone Propionate—CYP3A4—Tryptophan metabolism—MDM2—bone cancer	5.28e-05	0.00152	CbGpPWpGaD
Fluticasone Propionate—NR3C1—SIDS Susceptibility Pathways—JUN—bone cancer	5.22e-05	0.0015	CbGpPWpGaD
Fluticasone Propionate—CYP3A5—Metabolism—NDUFA12—bone cancer	5.16e-05	0.00148	CbGpPWpGaD
Fluticasone Propionate—PGR—Signaling Pathways—GRM1—bone cancer	5.12e-05	0.00147	CbGpPWpGaD
Fluticasone Propionate—PGR—Gene Expression—EZH2—bone cancer	5.05e-05	0.00145	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Signaling by GPCR—SMO—bone cancer	4.99e-05	0.00143	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Integrated Pancreatic Cancer Pathway—EGFR—bone cancer	4.93e-05	0.00142	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Signaling Pathways—GRM4—bone cancer	4.82e-05	0.00138	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Signaling Pathways—RGS1—bone cancer	4.82e-05	0.00138	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Hemostasis—PLAU—bone cancer	4.73e-05	0.00136	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Signaling by GPCR—GNA11—bone cancer	4.56e-05	0.00131	CbGpPWpGaD
Fluticasone Propionate—NR3C1—Gene Expression—NR1I2—bone cancer	4.55e-05	0.00131	CbGpPWpGaD
Fluticasone Propionate—CYP3A5—Metabolism—NT5C3A—bone cancer	4.27e-05	0.00123	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Signaling Pathways—GRM1—bone cancer	4.18e-05	0.0012	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Integrated Pancreatic Cancer Pathway—TP53—bone cancer	4.14e-05	0.00119	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Signaling by GPCR—IL3—bone cancer	4.14e-05	0.00119	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Metabolism—ENO2—bone cancer	3.72e-05	0.00107	CbGpPWpGaD
Fluticasone Propionate—PGR—Signaling Pathways—SMO—bone cancer	3.61e-05	0.00103	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Metabolism—DHFR—bone cancer	3.45e-05	0.000989	CbGpPWpGaD
Fluticasone Propionate—CYP3A4—Biological oxidations—GSTP1—bone cancer	3.42e-05	0.000982	CbGpPWpGaD
Fluticasone Propionate—CYP3A4—Metapathway biotransformation—GSTP1—bone cancer	3.38e-05	0.000968	CbGpPWpGaD
Fluticasone Propionate—NR3C1—Gene Expression—EIF2S1—bone cancer	3.36e-05	0.000964	CbGpPWpGaD
Fluticasone Propionate—PGR—Signaling Pathways—GNA11—bone cancer	3.3e-05	0.000946	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Metabolism—GNA11—bone cancer	3.22e-05	0.000925	CbGpPWpGaD
Fluticasone Propionate—PGR—Signaling Pathways—ATF1—bone cancer	3.07e-05	0.00088	CbGpPWpGaD
Fluticasone Propionate—PGR—Signaling Pathways—IL3—bone cancer	2.99e-05	0.000858	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Signaling Pathways—SMO—bone cancer	2.95e-05	0.000845	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Metabolism—CYP3A4—bone cancer	2.92e-05	0.000838	CbGpPWpGaD
Fluticasone Propionate—NR3C1—Gene Expression—EZH2—bone cancer	2.92e-05	0.000838	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	2.91e-05	0.000834	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Signaling Pathways—GNA11—bone cancer	2.69e-05	0.000773	CbGpPWpGaD
Fluticasone Propionate—CYP3A7—Metabolism—ENO2—bone cancer	2.59e-05	0.000743	CbGpPWpGaD
Fluticasone Propionate—PGR—Signaling Pathways—TGFBR2—bone cancer	2.56e-05	0.000734	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Signaling Pathways—ATF1—bone cancer	2.51e-05	0.000719	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Metabolism—GSTP1—bone cancer	2.5e-05	0.000717	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Signaling Pathways—IL3—bone cancer	2.44e-05	0.000701	CbGpPWpGaD
Fluticasone Propionate—PGR—Signaling Pathways—IGF1R—bone cancer	2.41e-05	0.00069	CbGpPWpGaD
Fluticasone Propionate—CYP3A7—Metabolism—DHFR—bone cancer	2.4e-05	0.000689	CbGpPWpGaD
Fluticasone Propionate—CYP3A4—Metabolism—NDUFA12—bone cancer	2.4e-05	0.000688	CbGpPWpGaD
Fluticasone Propionate—CYP3A7—Metabolism—GNA11—bone cancer	2.25e-05	0.000644	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Signaling Pathways—TGFBR2—bone cancer	2.09e-05	0.0006	CbGpPWpGaD
Fluticasone Propionate—CYP3A7—Metabolism—CYP3A4—bone cancer	2.04e-05	0.000584	CbGpPWpGaD
Fluticasone Propionate—CYP3A4—Metabolism—NT5C3A—bone cancer	1.99e-05	0.00057	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Signaling Pathways—IGF1R—bone cancer	1.97e-05	0.000564	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Hemostasis—TP53—bone cancer	1.9e-05	0.000545	CbGpPWpGaD
Fluticasone Propionate—CYP3A5—Metabolism—ENO2—bone cancer	1.87e-05	0.000537	CbGpPWpGaD
Fluticasone Propionate—PGR—Signaling Pathways—KIT—bone cancer	1.75e-05	0.000501	CbGpPWpGaD
Fluticasone Propionate—CYP3A7—Metabolism—GSTP1—bone cancer	1.74e-05	0.0005	CbGpPWpGaD
Fluticasone Propionate—CYP3A5—Metabolism—DHFR—bone cancer	1.74e-05	0.000498	CbGpPWpGaD
Fluticasone Propionate—PGR—Signaling Pathways—BRAF—bone cancer	1.64e-05	0.000471	CbGpPWpGaD
Fluticasone Propionate—CYP3A5—Metabolism—GNA11—bone cancer	1.62e-05	0.000466	CbGpPWpGaD
Fluticasone Propionate—CYP3A5—Metabolism—CYP3A4—bone cancer	1.47e-05	0.000422	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Signaling Pathways—KIT—bone cancer	1.43e-05	0.000409	CbGpPWpGaD
Fluticasone Propionate—PGR—Signaling Pathways—MDM2—bone cancer	1.37e-05	0.000394	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Signaling Pathways—BRAF—bone cancer	1.34e-05	0.000385	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Signaling by GPCR—EGFR—bone cancer	1.3e-05	0.000373	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Metabolism—PTGS2—bone cancer	1.29e-05	0.000371	CbGpPWpGaD
Fluticasone Propionate—CYP3A5—Metabolism—GSTP1—bone cancer	1.26e-05	0.000361	CbGpPWpGaD
Fluticasone Propionate—PGR—Signaling Pathways—JUN—bone cancer	1.19e-05	0.000343	CbGpPWpGaD
Fluticasone Propionate—PGR—Signaling Pathways—MMP9—bone cancer	1.16e-05	0.000334	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Signaling Pathways—MDM2—bone cancer	1.12e-05	0.000322	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Signaling Pathways—JUN—bone cancer	9.76e-06	0.00028	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Signaling Pathways—MMP9—bone cancer	9.5e-06	0.000272	CbGpPWpGaD
Fluticasone Propionate—PGR—Signaling Pathways—EGFR—bone cancer	9.39e-06	0.00027	CbGpPWpGaD
Fluticasone Propionate—CYP3A7—Metabolism—PTGS2—bone cancer	9.02e-06	0.000259	CbGpPWpGaD
Fluticasone Propionate—CYP3A4—Metabolism—ENO2—bone cancer	8.71e-06	0.00025	CbGpPWpGaD
Fluticasone Propionate—CYP3A4—Metabolism—DHFR—bone cancer	8.08e-06	0.000232	CbGpPWpGaD
Fluticasone Propionate—PGR—Signaling Pathways—TP53—bone cancer	7.89e-06	0.000226	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Signaling Pathways—EGFR—bone cancer	7.67e-06	0.00022	CbGpPWpGaD
Fluticasone Propionate—CYP3A4—Metabolism—GNA11—bone cancer	7.55e-06	0.000217	CbGpPWpGaD
Fluticasone Propionate—CYP3A5—Metabolism—PTGS2—bone cancer	6.52e-06	0.000187	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Signaling Pathways—TP53—bone cancer	6.44e-06	0.000185	CbGpPWpGaD
Fluticasone Propionate—CYP3A4—Metabolism—GSTP1—bone cancer	5.85e-06	0.000168	CbGpPWpGaD
Fluticasone Propionate—CYP3A4—Metabolism—PTGS2—bone cancer	3.03e-06	8.7e-05	CbGpPWpGaD
